Qiagen N.V.

Equities

QGEN

NL0015002CX3

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:02 2025-12-12 pm EST			5-day change	1st Jan Change
45.22 ^USD	-0.48%		-3.95%	-1.27%

Dec. 11	Citigroup Downgrades QGEN to Neutral From Buy, Price Target is $55	MT
Dec. 03	Qiagen N.V. Presents at Evercore 8th Annual Healthcare Conference, Dec-03-2025 10:50 AM

QIAGEN NV : Buy rating from Berenberg

Published on 11/11/2025 at 02:40 am EST

MarketScreener with dpa-AFX Analyser

Qiagen N.V.

-0.48%

In a research note, Berenberg analyst Harry Gillis has maintained his recommendation on the stock with a Buy rating. The target price has been revised downwards and is now set at EUR 46 as compared to EUR 50 previously.

Latest news about Qiagen N.V.

Dec. 11	Citigroup Downgrades QGEN to Neutral From Buy, Price Target is $55	MT
Dec. 03	Qiagen N.V. Presents at Evercore 8th Annual Healthcare Conference, Dec-03-2025 10:50 AM
Dec. 02	Qiagen N.V. Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 11:15 AM
Nov. 21	Qiagen N.V. - Special Call
Nov. 20	Oracle Corporation Names Stephen Rusckowski to the Board of Directors, Effective on November 18, 2025	CI
Nov. 20	Rebounds expected in Europe, focus on US reports	AN
Nov. 20	QIAGEN NV : Gets a Buy rating from Jefferies	ZD
Nov. 19	Qiagen N.V. Presents at Jefferies London Healthcare Conference 2025, Nov-19-2025 10:30 AM
Nov. 19	Diasorin and Qiagen, new test for the diagnosis of tuberculosis	AN
Nov. 18	Cellbxhealth, Qiagen Unit Enter Co-marketing Deal	MT
Nov. 17	Qiagen N.V. Presents at 7th Annual Wolfe Research Healthcare Conference, Nov-17-2025 12:40 PM
Nov. 17	Qiagen Seeks Acquisitions	CI
Nov. 11	QIAGEN NV : Deutsche Bank reiterates its Buy rating	ZD
Nov. 11	QIAGEN NV : DZ Bank reiterates its Buy rating	ZD
Nov. 11	QIAGEN NV : Buy rating from Berenberg	ZD
Nov. 10	QIAGEN N.V. Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025	CI
Nov. 05	Qiagen N.V., Q3 2025 Earnings Call, Nov 05, 2025
Nov. 05	Qiagen lifts adjusted EPS guidance after Q3 earnings beat and new acquisition
Nov. 05	Déjà Vu, With Better Balance Sheets
Nov. 05	QIAGEN NV : Deutsche Bank reiterates its Buy rating	ZD
Nov. 05	QIAGEN NV : UBS remains Neutral	ZD
Nov. 05	QIAGEN NV : Jefferies reiterates its Buy rating	ZD
Nov. 04	Qiagen N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 04	Qiagen N.V. Announces to Step Down of Thierry Bernard as CEO	CI
Nov. 04	Qiagen N.V. Reaffirms Earnings Guidance for the Fiscal Year 2025	CI

Chart Qiagen N.V.

Duration

Period

QGEN: Dynamic Chart

Company Profile

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Employees

5,700

Sector

Biotechnology & Medical Research

Calendar

Feb. 09 - Q4 2025 Earnings Release (Projected)

More about the company